BridgeMD
New treatment option for Infertility of Uterine Origin
Official title Platelet Rich Plasma for Insufficient Endometrium
ClinicalTrials.gov ID: NCT05538338
What this study is testing
- What it's testing
- To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45, women only
You may be able to join if
- Patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical...
- Patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo...
You likely can't join if
- Fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles.
- Most recent unsuccessful embryo transfer prior to January 1, 2017.
- Mullerian anomalies, excluding arcuate uterus
- Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery
- Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.
- Failure of patient to agree to enrollment in study with written consent.
See the full eligibility criteria
- Patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical pregnancy (visualization of intrauterine gestational sac on ultrasound or...
- Patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo transfer cycles.
- Fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles.
- Most recent unsuccessful embryo transfer prior to January 1, 2017.
- Mullerian anomalies, excluding arcuate uterus
- Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery
- Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.
- Failure of patient to agree to enrollment in study with written consent.
- Concurrent pregnancy
- Anticoagulation use for which plasma infusion is contraindicated
- History of thrombosis
- Thrombophilia either inherited or acquired
- Concomitant use of adjunctive therapies for proliferation. These must be discontinued upon enrollment.
- Embryo planned to be used for transfer generated from surgically obtained sperm due to a diagnosis of non-obstructive azoospermia
- Recurrent/persistent endometrial fluid in prior cycles
The study team makes the final eligibility decision.
Where it's taking place
- Basking Ridge, New Jersey, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Basking Ridge, New Jersey, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.